pharma · Oral Mucositis · Complex Cardiovascular Surgery With Cardiopulmonary Bypass
CSL Behring
CSL Behring GmbH
CSL Behring clinical programs — 7 development programs from ClinicalTrials.gov with phase, modality, indication, and trial identifiers.
Company details
- Status
- Public
- HQ
- Marburg, DE
- Programs
- 7
- Drugs
- 6
- Patents
- 25
CSL Behring projects
7 ClinicalTrials.gov programs sponsored by CSL Behring.
CSL Behring has 7 clinical development programs indexed from ClinicalTrials.gov, including phase, modality, indication text, and linked NCT identifiers.
Clinical programs
-
BE1116
CSL Behring GmbH
Complex Cardiovascular Surgery With Cardiopulmonary Bypass
1 trial -
CSL689
CSL Behring GmbH
Hemophilia A With Inhibitors
1 trial -
Clazakizumab
CSL Behring GmbH
Antibody-mediated Rejection
1 trial -
human immunoglobulin G
CSL Behring GmbH
Dermatomyositis
1 trial -
ALD518
CSL Behring GmbH
Oral Mucositis
1 trial -
BMS-945429 Placebo
CSL Behring GmbH
Rheumatoid Arthritis
1 trial -
CSL760
CSL Behring GmbH
Coronavirus Disease 2019 (COVID-19)
1 trial
Frequently asked questions
How many clinical projects does CSL Behring have?
7 published programs are linked to this sponsor in our ClinicalTrials.gov index.
Is this the complete company pipeline?
This directory lists published programs for the sponsor in our database. Partnered or out-licensed assets may appear under multiple companies.